Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Ventyx Biosciences, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ventyx Biosciences, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences. The company focuses on developing oral therapies for inflammatory diseases. Executives will provide company insights during the 2022 Wells Fargo Healthcare Conference on September 9, 2022, at 8:00 AM ET in Boston, MA, and at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 4:40 PM ET in New York, NY. Webcasts of the presentations will be available on their website.
Details
News Market Reaction – VTYX
The recorded move for VTYX in the trading session of this news was -1.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ENCINITAS, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that Company executives will host investor meetings and provide a company overview during fireside chats at the following upcoming investor conferences:
- Event: 2022 Wells Fargo Healthcare Conference
Location: Boston, MA
Date: Friday, September 9, 2022
Time: 8:00-8:30 AM ET - Event: Morgan Stanley 20th Annual Global Healthcare Conference
Location: New York, NY
Date: Wednesday, September 14, 2022
Time: 4:40-5:10 PM ET
Webcasts of both presentations will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of each event for 30 days.
About Ventyx Biosciences
Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three clinical-stage internally discovered programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit www.ventyxbio.com.
Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.